He is an accomplished drug hunter and inventor of the Factor Xa inhibitor blockbuster rivaroxaban (Xarelto(R)) and of the sGC stimulator riociguat (Adempas (R)), both from Bayer AG.
With over 25 years’ experience in intellectual property (IP) for the pharmaceutical and chemical industry, Colin manages the company’s IP portfolio and drives the general IP strategy to protect FundaMental Pharma’s pipeline assets.
Combining the precision of high-level executive support with the foresight of operational leadership, she manages complex schedules, oversees critical projects, and acts as a trusted liaison with boards, investors, and key stakeholders.
Founded as a spin-off from the Heidelberg University, Germany, FundaMental Pharma has established its independent operations at BioLabs in Heidelberg since 2023.
The page states that FMP374, an orally bioavailable clinical candidate, is prepared for IND-enabling studies with no showstopper identified in preclinical support.
